DAIC

MARCH 31, 2025

tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. Reardon, M.D.,

TAVR 52

TAVR Stenosis Aortic Outcomes 52

DAIC

JANUARY 29, 2024

From a pool of 37,011 patients, the study identified 2,360 patients under the age of 60 years who underwent these procedures, with 22% receiving TAVR and 78% SAVR. By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. years after TAVR and 4.9 years after SAVR to assess their outcomes.

Aortic valve 111

Aortic valve TAVR Aortic Outcomes 111

DAIC

APRIL 30, 2024

As cardiothoracic surgery continues to evolve, STS has responded by adding new risk models to guide treatment decisions and benchmark performance,” said STS President Jennifer C. SAVR after TAVR Surgical aortic valve replacement after prior TAVR is the fastest-growing cardiac surgery procedure in the U.S. and 3.8%, respectively.

TAVR 111

TAVR Aortic valve Tricuspid Coronary Artery Bypass Graft 111

DAIC

JANUARY 29, 2024

The conference, healthcare’s leading scientific and educational convening specializing in cardiothoracic surgery, has a rich history of showcasing clinical trials with a strong foundation of detailed methodology and trusted data collection governed by ethical clinical principles.

Research 111

Research TAVR Aortic valve Atrial Fibrillation 111

DAIC

MARCH 12, 2024

milla1cf Tue, 03/12/2024 - 16:48 March 12, 2024 — Medtronic plc , a global leader in healthcare technology, today announced two late-breaking data presentations on four-year outcomes from the Evolut Low Risk Trial. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.

TAVR 52

TAVR Aortic valve Aortic Stenosis 52

Society of Thoracic Surgeons - Technology

OCTOBER 21, 2021

Removing these barriers would allow surgeons, physicians, hospitals, health systems, and others to conduct longitudinal analyses and gain new insights into long-term outcomes for patients undergoing procedures such as coronary artery bypass grafting (CABG)—the most common operation performed by cardiac surgeons.

Technology 40

Technology Coronary Artery Bypass Graft Cardiothoracic Aortic valve 40

Society of Thoracic Surgeons - Congenital

JANUARY 25, 2025

The study, leveraging data from the STS Adult Cardiac Surgery Database (ACSD), offers the most comprehensive analysis to date of prosthetic valve outcomes, encompassing over 100,000 patients. The study addressed a critical question in cardiac surgery: how age and valve type influence outcomes for patients undergoing surgical AVR.

Aortic valve 75

Aortic valve Aortic Cardiothoracic Cancer 75